1996-2021年爱尔兰肌萎缩侧索硬化的流行病学趋势
基于爱尔兰全国ALS登记处25年数据,共识别2771例患者,粗发病率从2.64升至5.46/10万,标化发病率从2.64升至3.1/10万,患病率从5.83升至8.10/10万,中位发病年龄从64岁增至67岁,三个时段生存无显著差异。
要点
- 粗发病率从2.64升至5.46/10万,标化发病率从2.64升至3.1/10万。
- 患病率从5.83升至8.10/10万,中位发病年龄从64岁增至67岁。
- 发病高峰年龄从70-74岁移至75-79岁,三个时段生存无显著差异。
核心结论
- 爱尔兰ALS的年龄标化总发病率、发病高峰、患病率和发病年龄在25年间均上升。
- 尽管广泛使用无创通气、积极气道分泌物管理及ALS照护变化,爱尔兰人群平均生存未改变。
研究设计与样本
- 基于爱尔兰全国ALS登记处(自1994年持续运行)估算1996-2021年发病和患病病例。
- 发病病例采用直接法年龄标化并应用于爱尔兰、欧洲和美国3个标准人群。
- 生存分析采用Kaplan-Meier曲线和Cox回归模型,非正态分布组采用Kruskal-Wallis检验及Bonferroni校正。
主要发现
- 25年间共识别2771例ALS患者,发病率按15岁以上人群计算。
- 粗发病率从2.64升至5.46/10万,标化发病率从2.64升至3.1/10万,患病率从5.83升至8.10/10万。
- 中位发病年龄从64岁增至67岁,发病高峰年龄从70-74岁移至75-79岁。
- 女性中位发病年龄67岁 consistently 晚于男性65岁(p < 0.001)。
- 三个时段(1996-2003、2004-2012、2013-2021)生存无显著差异;多因素Cox回归显示发病年龄较大为生存负预测因素(HR 1.03,CI 1.02-1.04,p < 0.001),利鲁唑使用(HR 0.67,CI 0.50-0.90,p = 0.033)和诊断延迟(HR 0.98,CI 0.98-0.99,p < 0.001)为正向预测因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The objective of this study was to examine changes to the incidence, prevalence, age at onset, and survival of patients diagnosed with amyotrophic lateral sclerosis (ALS) in the Republic of Ireland over 25 years. METHODS: Incident and prevalent cases of ALS were estimated using the Irish population-based ALS Register, which has been in continuous operation since 1994. Incident cases were age standardized using the direct method and applied to 3 standard populations (Irish, European, and American). Survival was determined using Kaplan-Meier curves and Cox regression models. Non-normally distributed groups were compared using the Kruskal-Wallis test with a Bonferroni correction. RESULTS: A total of 2,771 patients with ALS were identified in the Republic of Ireland over 25 years. Incidence per 100,000 was determined for the population older than 15 years. Crude incidence increased from 2.64 to 5.46 per 100,000. Standardized incidence increased from 2.64 to 3.1 per 100,000. Prevalence increased from 5.83 to 8.10 per 100,000. The median age at onset increased from 64 to 67 years. The peak age of incidence increased from those between 70 and 74 years to those between 75 and 79 years. Overall, women had a consistently later median age at onset of 67 years compared with men at 65 years (p < 0.001). No significant difference in survival was noted between those captured across 3 different epochs (1996-2003, 2004-2012, 2013-2021). Older age at onset (hazard ratio [HR] 1.03, CI 1.02-1.04, p < 0.001) was a negative predictive factor of survival in multivariate Cox regression analysis. Riluzole use (HR 0.67, CI 0.50-0.90, p = 0.033) and diagnostic delay (HR 0.98, CI 0.98-0.99, p < 0.001) were positive predictive factors. DISCUSSION: Within the Republic of Ireland, the age-standardized overall incidence, peak incidence, prevalence, and age at onset of ALS have all increased over 25 years. Despite the widespread use of noninvasive ventilation, aggressive secretion management, and changes in ALS care, the mean survival within the Irish population has not changed.
引用
- McFarlane R, Peelo C, Galvin M, et al. Epidemiologic Trends of Amyotrophic Lateral Sclerosis in Ireland, 1996-2021. Neurology. 2023. PMID: 37748881. doi:10.1212/WNL.0000000000207797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。